Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE)

The safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine (PCV), were assessed in a pivotal phase III trial conducted in healthy adults ≥50 years of age (NCT03950622, Japic-CTI 194845). We performed a subgroup analysis of 245 Japanese participants (all ≥65 years of age). The...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Japanese Journal of Infectious Diseases 2022/11/30, Vol.75(6), pp.575-582
Hauptverfasser:	Kishino, Hiroyuki, Sawata, Miyuki, Igarashi, Rie, Shirakawa, Masayoshi, Pedley, Alison, Musey, Luwy, Platt, Heather Loryn, Buchwald, Ulrike Kirsten
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Age Conjugates Evaluation Immune response Immunization Immunogenicity Japanese adults pneumococcal conjugate vaccine Population studies Safety Serotypes Subgroups Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!